{ "schemaVersion": 1, "organisationId": "O-5b33e00e75324ef48f0f33ed9b069c72", "slug": "hutchmed-china-ltd", "name": "HUTCHMED (China) Ltd", "updatedAt": "2026-10-02T12:18:36.751746Z", "sections": [ { "type": "OVERVIEW", "text": "HUTCHMED (China) Ltd is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on targeted therapies and immunotherapies for cancer and immunological diseases. Its marketed oncology medicines include fruquintinib, surufatinib and savolitinib. Founded in 2000, the company is based in China and pursues international development and commercialization; fruquintinib had approvals in more than 30 countries by the first half of 2025. [D357415][P150036301][P150035393][https://www.hutch-med.com/about-us/][https://www.hutch-med.com/what-we-do/][https://www.hutch-med.com/2025-half-year-results/]\n\nThe company states its mission is to bring innovative therapies to patients across the globe. For the year ended 31 December 2025, HUTCHMED reported total revenue of US$548.512 million and 1,796 employees at year-end. [https://www.hutch-med.com/what-we-do/research-and-development/][D357415]\n[D357415][P150036301][P150035393][D357415][D357415][https://www.hutch-med.com/about-us/][https://www.hutch-med.com/what-we-do/][https://www.hutch-med.com/2025-half-year-results/][https://www.hutch-med.com/what-we-do/research-and-development/]", "updatedAt": "2026-10-02T12:18:36.751746Z" }, { "type": "PRODUCTS", "text": "HUTCHMED’s marketed oncology products include fruquintinib, sold in China as Elunate and outside China as Fruzaqla. Elunate is used for third-line colorectal cancer (CRC); the company also reports a conditional China approval with Tyvyt for second-line pMMR endometrial cancer. In 2025, Elunate in-market sales were US$100.1 million, of which US$76.9 million was consolidated by HUTCHMED. Fruzaqla is marketed by Takeda outside China for third-line CRC; its 2025 in-market sales were US$366.2 million, while HUTCHMED recorded US$89.4 million in manufacturing and royalty revenue. [P150036102][P150036105][P150036106]\n\nSurufatinib, marketed in China as Sulanda, is supplied as capsules for advanced non-pancreatic and pancreatic neuroendocrine tumors; the report identifies a 50 mg dosage form. HUTCHMED retains worldwide rights, and Sulanda revenue was US$27.0 million in 2025. [P150036345] Savolitinib, marketed as Orpathys with AstraZeneca, is approved in China for MET exon 14-skipping non-small cell lung cancer (NSCLC), including treatment-naïve patients, and with Tagrisso for second-line EGFR-mutated NSCLC with MET amplification. Its 2025 in-market sales were US$28.9 million and HUTCHMED consolidated revenue was US$18.6 million; a separate US$11.0 million milestone followed a China approval. [P150037418][P150036194][P150036116]\n\nCommercial activities disclosed include HUTCHMED’s detailing, promotion and marketing of Elunate in China for Lilly, and manufacturing and royalty revenue for partnered products. The company reports US$214.356 million of 2025 external-customer revenue for its Oncology/Immunology Marketed Products segment, but does not provide product-level percentages of total company performance. [P150036105][P150036106][P150036116][T17166664]\n[P150036102][P150036105][P150036106][P150036345][P150037418][P150036194][P150036116][T17166664]", "updatedAt": "2026-10-02T12:18:36.751746Z" }, { "type": "GEOGRAPHY", "text": "HUTCHMED’s operations are centered in China, with research, office and manufacturing facilities in Shanghai and Suzhou, Jiangsu. Its 2025 filing identifies a 5,024 m² Shanghai R&D facility, 9,080 m² of Shanghai office and laboratory space, and a 4,968 m² GMP manufacturing site in Suzhou. It also reports a nearly 55,000 m² Shanghai manufacturing facility. [P150037110][P150037150]\n\nThe company’s official contact information lists its principal executive office in Kowloon, Hong Kong, as well as locations in Shanghai and Suzhou. [https://www.hutch-med.com/about-us/contact-us/] HUTCHMED reported an approximately 780-person in-house oncology commercial organization based in Shanghai, Suzhou, Beijing and other locations, alongside approximately 860 scientists and staff; a country-by-country employee breakdown was not provided. [https://www.hutch-med.com/wp-content/uploads/2026/08/e_2026_interim-2.pdf]\n\nChina is a core sales market, while partner commercialization extends key products internationally. For example, FRUZAQLA had approvals or launches in 41 countries by H1 2026; Takeda holds rights outside mainland China, Hong Kong and Macau. HUTCHMED reported FRUZAQLA global in-market sales of $185.4 million in H1 2026, including $68.9 million outside the U.S.; ELUNATE in-market sales in China were $60.8 million. These are product in-market sales, not HUTCHMED revenue by geography. The materials reviewed did not provide a country- or region-level breakdown of company revenue or its percentage of consolidated revenue. [https://www.hutch-med.com/wp-content/uploads/2026/07/a260730.pdf][https://www.hutch-med.com/2026-half-year-results/]\n\nManufacturing is also geographically concentrated in China: the filing describes production of fruquintinib and surufatinib finished products there, while ex-China fruquintinib supply may also come from a third-party manufacturer in Switzerland. [P150035725]\n[P150037110][P150037150][https://www.hutch-med.com/about-us/contact-us/][https://www.hutch-med.com/wp-content/uploads/2026/08/e_2026_interim-2.pdf][https://www.hutch-med.com/wp-content/uploads/2026/07/a260730.pdf][https://www.hutch-med.com/2026-half-year-results/][P150035725][https://www.hutch-med.com/about-us/contact-us/][https://www.hutch-med.com/wp-content/uploads/2026/08/e_2026_interim-2.pdf][https://www.hutch-med.com/wp-content/uploads/2026/07/a260730.pdf][https://www.hutch-med.com/2026-half-year-results/]", "updatedAt": "2026-10-02T12:18:36.751746Z" }, { "type": "SEGMENTS", "text": "HUTCHMED’s latest reported segment results are for the six months ended 30 June 2026. It reports two operating segments: **Oncology/Immunology**, focused on discovering, developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases; and **Other Ventures**, covering other commercial businesses, including the sale, marketing, manufacture and distribution of prescription drugs and healthcare products. [P150038432][P150038433][https://www.hutch-med.com/interim-report-2026/]\n\nFor that period, Oncology/Immunology generated US$162.3 million, approximately **58.3%** of total revenue, and Other Ventures generated US$116.0 million, approximately **41.7%** of total revenue; total revenue was US$278.3 million. Percentages are calculated from reported segment revenue. [https://www.hutch-med.com/interim-report-2026/][https://www.hutch-med.com/2026-half-year-results/]\n[P150038432][P150038433][https://www.hutch-med.com/interim-report-2026/][https://www.hutch-med.com/2026-half-year-results/]", "updatedAt": "2026-10-02T12:18:36.751746Z" }, { "type": "HISTORY", "text": "HUTCHMED traces its origins to 2000. Its Hutchison MediPharma business was established in 2002 to develop traditional Chinese medicine and expanded into small-molecule drug discovery and development in 2005. The company listed on London’s AIM in 2006. [https://www.hutch-med.com/about-us/][https://www.hutch-med.com/wp-content/uploads/docArchive/pdf/news131010e.pdf][https://www.hutch-med.com/wp-content/uploads/docArchive/announcements/a060519.pdf]\n\nThe company expanded its oncology portfolio through a series of China regulatory milestones: fruquintinib was approved in 2018 for metastatic colorectal cancer, surufatinib in 2020 for non-pancreatic neuroendocrine tumors, and savolitinib received conditional approval in 2021. [https://www.hutch-med.com/approval-fruquintinib-colorectal-cancer-china/][https://www.hutch-med.com/chi-med-announces-the-nmpa-approval-of-surufatinib-sulanda-in-china-for-epnet/][https://www.hutch-med.com/savolitinib-approved-in-china-for-patients-with-lung-cancer-with-met-exon-14-skipping-alterations/]\n\nIn 2021, the company brought its Chi-Med and Hutchison MediPharma identities together under the HUTCHMED name, changed its legal name to HUTCHMED (China) Limited, and completed a primary listing in Hong Kong, in addition to its existing listings. [https://www.hutch-med.com/chi-med-becomes-hutchmed/][https://www.hutch-med.com/change-of-company-name/][https://www.hutch-med.com/closing-of-the-global-offering-and-the-primary-listing-in-hong-kong/] In 2023, it licensed fruquintinib rights outside mainland China, Hong Kong and Macau to Takeda; the medicine subsequently gained U.S. approval in 2023 and European Commission approval in 2024. [https://www.hutch-med.com/wp-content/uploads/2023/01/a230123_fru.pdf][https://www.hutch-med.com/us-fda-approval-of-fruzaqla-fruquintinib/][https://www.hutch-med.com/european-commission-approval-for-fruzaqla-fruquintinib/] In 2025, HUTCHMED completed the sale of its 45% interest in Shanghai Hutchison Pharmaceuticals. [P150036157]\n[P150036157][https://www.hutch-med.com/about-us/][https://www.hutch-med.com/wp-content/uploads/docArchive/pdf/news131010e.pdf][https://www.hutch-med.com/wp-content/uploads/docArchive/announcements/a060519.pdf][https://www.hutch-med.com/approval-fruquintinib-colorectal-cancer-china/][https://www.hutch-med.com/chi-med-announces-the-nmpa-approval-of-surufatinib-sulanda-in-china-for-epnet/][https://www.hutch-med.com/savolitinib-approved-in-china-for-patients-with-lung-cancer-with-met-exon-14-skipping-alterations/][https://www.hutch-med.com/chi-med-becomes-hutchmed/][https://www.hutch-med.com/change-of-company-name/][https://www.hutch-med.com/closing-of-the-global-offering-and-the-primary-listing-in-hong-kong/][https://www.hutch-med.com/wp-content/uploads/2023/01/a230123_fru.pdf][https://www.hutch-med.com/us-fda-approval-of-fruzaqla-fruquintinib/][https://www.hutch-med.com/european-commission-approval-for-fruzaqla-fruquintinib/]", "updatedAt": "2026-10-02T12:18:36.751746Z" } ], "sources": [ { "id": "D357415", "href": "https://app.finbar.com/go?id=D357415", "label": "HUTCHMED (China) Ltd — Full financial report (2025 Y)", "documentId": "D-d2c0e9cfe47e4fc399974c5edf616244" }, { "id": "P150036301", "href": "https://app.finbar.com/go?id=P150036301", "label": "HUTCHMED (China) Ltd — Full financial report (2025 Y)", "documentId": "D-d2c0e9cfe47e4fc399974c5edf616244" }, { "id": "P150035393", "href": "https://app.finbar.com/go?id=P150035393", "label": "HUTCHMED (China) Ltd — Full financial report (2025 Y)", "documentId": "D-d2c0e9cfe47e4fc399974c5edf616244" }, { "id": "https://www.hutch-med.com/about-us/", "href": "https://www.hutch-med.com/about-us/", "label": "www.hutch-med.com" }, { "id": "https://www.hutch-med.com/what-we-do/", "href": "https://www.hutch-med.com/what-we-do/", "label": "www.hutch-med.com" }, { "id": "https://www.hutch-med.com/2025-half-year-results/", "href": "https://www.hutch-med.com/2025-half-year-results/", "label": "www.hutch-med.com" }, { "id": "https://www.hutch-med.com/what-we-do/research-and-development/", "href": "https://www.hutch-med.com/what-we-do/research-and-development/", "label": "www.hutch-med.com" }, { "id": "P150036102", "href": "https://app.finbar.com/go?id=P150036102", "label": "HUTCHMED (China) Ltd — Full financial report (2025 Y)", "documentId": "D-d2c0e9cfe47e4fc399974c5edf616244" }, { "id": "P150036105", "href": "https://app.finbar.com/go?id=P150036105", "label": "HUTCHMED (China) Ltd — Full financial report (2025 Y)", "documentId": "D-d2c0e9cfe47e4fc399974c5edf616244" }, { "id": "P150036106", "href": "https://app.finbar.com/go?id=P150036106", "label": "HUTCHMED (China) Ltd — Full financial report (2025 Y)", "documentId": "D-d2c0e9cfe47e4fc399974c5edf616244" }, { "id": "P150036345", "href": "https://app.finbar.com/go?id=P150036345", "label": "HUTCHMED (China) Ltd — Full financial report (2025 Y)", "documentId": "D-d2c0e9cfe47e4fc399974c5edf616244" }, { "id": "P150037418", "href": "https://app.finbar.com/go?id=P150037418", "label": "HUTCHMED (China) Ltd — Full financial report (2025 Y)", "documentId": "D-d2c0e9cfe47e4fc399974c5edf616244" }, { "id": "P150036194", "href": "https://app.finbar.com/go?id=P150036194", "label": "HUTCHMED (China) Ltd — Full financial report (2025 Y)", "documentId": "D-d2c0e9cfe47e4fc399974c5edf616244" }, { "id": "P150036116", "href": "https://app.finbar.com/go?id=P150036116", "label": "HUTCHMED (China) Ltd — Full financial report (2025 Y)", "documentId": "D-d2c0e9cfe47e4fc399974c5edf616244" }, { "id": "T17166664", "href": "https://app.finbar.com/go?id=T17166664", "label": "HUTCHMED (China) Ltd — Full financial report (2025 Y)", "documentId": "D-d2c0e9cfe47e4fc399974c5edf616244" }, { "id": "P150037110", "href": "https://app.finbar.com/go?id=P150037110", "label": "HUTCHMED (China) Ltd — Full financial report (2025 Y)", "documentId": "D-d2c0e9cfe47e4fc399974c5edf616244" }, { "id": "P150037150", "href": "https://app.finbar.com/go?id=P150037150", "label": "HUTCHMED (China) Ltd — Full financial report (2025 Y)", "documentId": "D-d2c0e9cfe47e4fc399974c5edf616244" }, { "id": "https://www.hutch-med.com/about-us/contact-us/", "href": "https://www.hutch-med.com/about-us/contact-us/", "label": "www.hutch-med.com" }, { "id": "https://www.hutch-med.com/wp-content/uploads/2026/08/e_2026_interim-2.pdf", "href": "https://www.hutch-med.com/wp-content/uploads/2026/08/e_2026_interim-2.pdf", "label": "www.hutch-med.com" }, { "id": "https://www.hutch-med.com/wp-content/uploads/2026/07/a260730.pdf", "href": "https://www.hutch-med.com/wp-content/uploads/2026/07/a260730.pdf", "label": "www.hutch-med.com" }, { "id": "https://www.hutch-med.com/2026-half-year-results/", "href": "https://www.hutch-med.com/2026-half-year-results/", "label": "www.hutch-med.com" }, { "id": "P150035725", "href": "https://app.finbar.com/go?id=P150035725", "label": "HUTCHMED (China) Ltd — Full financial report (2025 Y)", "documentId": "D-d2c0e9cfe47e4fc399974c5edf616244" }, { "id": "P150038432", "href": "https://app.finbar.com/go?id=P150038432", "label": "HUTCHMED (China) Ltd — Full financial report (2025 Y)", "documentId": "D-d2c0e9cfe47e4fc399974c5edf616244" }, { "id": "P150038433", "href": "https://app.finbar.com/go?id=P150038433", "label": "HUTCHMED (China) Ltd — Full financial report (2025 Y)", "documentId": "D-d2c0e9cfe47e4fc399974c5edf616244" }, { "id": "https://www.hutch-med.com/interim-report-2026/", "href": "https://www.hutch-med.com/interim-report-2026/", "label": "www.hutch-med.com" }, { "id": "https://www.hutch-med.com/wp-content/uploads/docArchive/pdf/news131010e.pdf", "href": "https://www.hutch-med.com/wp-content/uploads/docArchive/pdf/news131010e.pdf", "label": "www.hutch-med.com" }, { "id": "https://www.hutch-med.com/wp-content/uploads/docArchive/announcements/a060519.pdf", "href": "https://www.hutch-med.com/wp-content/uploads/docArchive/announcements/a060519.pdf", "label": "www.hutch-med.com" }, { "id": "https://www.hutch-med.com/approval-fruquintinib-colorectal-cancer-china/", "href": "https://www.hutch-med.com/approval-fruquintinib-colorectal-cancer-china/", "label": "www.hutch-med.com" }, { "id": "https://www.hutch-med.com/chi-med-announces-the-nmpa-approval-of-surufatinib-sulanda-in-china-for-epnet/", "href": "https://www.hutch-med.com/chi-med-announces-the-nmpa-approval-of-surufatinib-sulanda-in-china-for-epnet/", "label": "www.hutch-med.com" }, { "id": "https://www.hutch-med.com/savolitinib-approved-in-china-for-patients-with-lung-cancer-with-met-exon-14-skipping-alterations/", "href": "https://www.hutch-med.com/savolitinib-approved-in-china-for-patients-with-lung-cancer-with-met-exon-14-skipping-alterations/", "label": "www.hutch-med.com" }, { "id": "https://www.hutch-med.com/chi-med-becomes-hutchmed/", "href": "https://www.hutch-med.com/chi-med-becomes-hutchmed/", "label": "www.hutch-med.com" }, { "id": "https://www.hutch-med.com/change-of-company-name/", "href": "https://www.hutch-med.com/change-of-company-name/", "label": "www.hutch-med.com" }, { "id": "https://www.hutch-med.com/closing-of-the-global-offering-and-the-primary-listing-in-hong-kong/", "href": "https://www.hutch-med.com/closing-of-the-global-offering-and-the-primary-listing-in-hong-kong/", "label": "www.hutch-med.com" }, { "id": "https://www.hutch-med.com/wp-content/uploads/2023/01/a230123_fru.pdf", "href": "https://www.hutch-med.com/wp-content/uploads/2023/01/a230123_fru.pdf", "label": "www.hutch-med.com" }, { "id": "https://www.hutch-med.com/us-fda-approval-of-fruzaqla-fruquintinib/", "href": "https://www.hutch-med.com/us-fda-approval-of-fruzaqla-fruquintinib/", "label": "www.hutch-med.com" }, { "id": "https://www.hutch-med.com/european-commission-approval-for-fruzaqla-fruquintinib/", "href": "https://www.hutch-med.com/european-commission-approval-for-fruzaqla-fruquintinib/", "label": "www.hutch-med.com" }, { "id": "P150036157", "href": "https://app.finbar.com/go?id=P150036157", "label": "HUTCHMED (China) Ltd — Full financial report (2025 Y)", "documentId": "D-d2c0e9cfe47e4fc399974c5edf616244" } ] }